Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CLPP | Q16740 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601066 | 1.00 | GRM5 (0.40) | GRM5HCRTR1HCRTR2HSD11B1RAB9A | |
| SCHEMBL7876409 | 0.90 | HCRTR1 (0.40) | GRM5HCRTR1HCRTR2RAB9ANPC1 | |
| SCHEMBL599809 | 0.89 | GRM5 (0.47) | GRM5HCRTR1HCRTR2HSD11B1RAB9A | |
| SCHEMBL600492 | 0.88 | PROKR1 (0.42) | GRM5HCRTR1HCRTR2HSD11B1RAB9A | |
| SCHEMBL600389 | 0.88 | GRM5 (0.40) | GRM5HCRTR1HCRTR2HSD11B1CLPP | |
| SCHEMBL7879774 | 0.88 | GRM5 (0.49) | GRM5HSD11B1CLPP | |
| SCHEMBL599414 | 0.88 | GRM5 (0.49) | GRM5HSD11B1CLPP | |
| SCHEMBL1971600 | 0.86 | HSD11B1 (0.55) | GRM5HSD11B1RAB9ANPC1CLPP | |
| SCHEMBL1971595 | 0.86 | HSD11B1 (0.55) | GRM5HSD11B1RAB9ANPC1CLPP | |
| SCHEMBL30795726 | 0.86 | HSD11B1 (0.52) | GRM5HSD11B1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |